Indivior Study Finds 300-mg SUBLOCADE Dose More Effective for High-Frequency Fentanyl Users

Reuters2025-12-18

Indivior Study Finds 300-mg SUBLOCADE Dose More Effective for High-Frequency Fentanyl Users

Indivior plc announced results from a randomized, double-blind clinical trial published in JAMA Network Open evaluating extended-release buprenorphine (SUBLOCADE®) for moderate-to-severe opioid use disorder. The study found that both 100-mg and 300-mg monthly maintenance doses of SUBLOCADE rapidly reduced opioid use and improved abstinence, with no new safety signals identified. Post-hoc analyses indicated the 300-mg dose performed significantly better than the 100-mg dose in participants reporting high-frequency fentanyl use. Injection-site reactions were more common at the higher dose but were mild to moderate and did not lead to discontinuation. The results have already been presented.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Indivior plc published the original content used to generate this news brief via PR Newswire (Ref. ID: PH49913) on December 17, 2025, and is solely responsible for the information contained therein.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2592914539?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-12-18 00:30","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2592914539","market":"fut","top_or_hot":-1,"title":"Indivior Study Finds 300-mg SUBLOCADE Dose More Effective for High-Frequency Fentanyl Users","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      Indivior Study Finds 300-mg SUBLOCADE Dose More Effective for High-Frequency Fentanyl Users\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        Indivior plc announced results from a randomized, double-blind clinical trial published in JAMA Network Open evaluating extended-release buprenorphine (SUBLOCADE®) for moderate-to-severe opioid use disorder. The study found that both 100-mg and 300-mg monthly maintenance doses of SUBLOCADE rapidly reduced opioid use and improved abstinence, with no new safety signals identified. Post-hoc analyses indicated the 300-mg dose performed significantly better than the 100-mg dose in participants reporting high-frequency fentanyl use. Injection-site reactions were more common at the higher dose but were mild to moderate and did not lead to discontinuation. The results have already been presented.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<i>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Indivior plc published the original content used to generate this news brief via PR Newswire (Ref. ID: PH49913) on December 17, 2025, and is solely responsible for the information contained therein.</span></i>\n</div></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Indivior Study Finds 300-mg SUBLOCADE Dose More Effective for High-Frequency Fentanyl Users</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nIndivior Study Finds 300-mg SUBLOCADE Dose More Effective for High-Frequency Fentanyl Users\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2025-12-18 00:30</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      Indivior Study Finds 300-mg SUBLOCADE Dose More Effective for High-Frequency Fentanyl Users\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        Indivior plc announced results from a randomized, double-blind clinical trial published in JAMA Network Open evaluating extended-release buprenorphine (SUBLOCADE®) for moderate-to-severe opioid use disorder. The study found that both 100-mg and 300-mg monthly maintenance doses of SUBLOCADE rapidly reduced opioid use and improved abstinence, with no new safety signals identified. Post-hoc analyses indicated the 300-mg dose performed significantly better than the 100-mg dose in participants reporting high-frequency fentanyl use. Injection-site reactions were more common at the higher dose but were mild to moderate and did not lead to discontinuation. The results have already been presented.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<i>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Indivior plc published the original content used to generate this news brief via PR Newswire (Ref. ID: PH49913) on December 17, 2025, and is solely responsible for the information contained therein.</span></i>\n</div></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"INDV","symbol_name":"INDIVIOR PLC","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251217:nNDLb3x9Px:1","article_id":"2592914539","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2592914539","pubTimestamp":1765989020,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"Indivior plc announced results from a randomized, double-blind clinical trial published in JAMA Network Open evaluating extended-release buprenorphine  for moderate-to-severe opioid use disorder. The study found that both 100-mg and 300-mg monthly maintenance doses of SUBLOCADE rapidly reduced opioid use and improved abstinence, with no new safety signals identified. Post-hoc analyses indicated the 300-mg dose performed significantly better than the 100-mg dose in participants reporting high-frequency fentanyl use. Injection-site reactions were more common at the higher dose but were mild to moderate and did not lead to discontinuation. The results have already been presented.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Indivior plc","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"INDV":"INDIVIOR PLC","BK4007":"制药"},"translate_title":"Indivior研究发现300 mg sublocade剂量对高频芬太尼使用者更有效","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"INDV":0.9},"content_text":"Indivior Study Finds 300-mg SUBLOCADE Dose More Effective for High-Frequency Fentanyl Users\n    \n\n        Indivior plc announced results from a randomized, double-blind clinical trial published in JAMA Network Open evaluating extended-release buprenorphine (SUBLOCADE®) for moderate-to-severe opioid use disorder. The study found that both 100-mg and 300-mg monthly maintenance doses of SUBLOCADE rapidly reduced opioid use and improved abstinence, with no new safety signals identified. Post-hoc analyses indicated the 300-mg dose performed significantly better than the 100-mg dose in participants reporting high-frequency fentanyl use. Injection-site reactions were more common at the higher dose but were mild to moderate and did not lead to discontinuation. The results have already been presented.\n      \n\nDisclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Indivior plc published the original content used to generate this news brief via PR Newswire (Ref. ID: PH49913) on December 17, 2025, and is solely responsible for the information contained therein.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"dataReport","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.36.0","shortVersion":"4.36.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2592914539","isCrawlerRequest":true}